HIV相关淋巴瘤的最新进展。
Update in HIV-associated lymphoma.
作者信息
Noy Ariela
机构信息
Division of Hematology, Memorial Sloan-Kettering Cancer, Weill Medical College of Cornell University, New York, New York 10021, USA.
出版信息
Curr Opin Oncol. 2004 Sep;16(5):450-4. doi: 10.1097/00001622-200409000-00007.
PURPOSE OF REVIEW
Infection with human immunodeficiency virus (HIV) is associated with an increased risk of non-Hodgkin lymphoma and Hodgkin disease. This review summarizes developments within the past 18 months.
RECENT FINDINGS
Investigators continue to demonstrate that many standard therapies similar to those used in the non-HIV- infected population may be used in the HAART era for patients infected with HIV. Biologic differences do exist, however, and not all treatments and outcomes are directly translatable. Some treatments, such as rituximab in combination with CHOP, may have unforeseen toxicity. Nonetheless, high-dose therapy does appear feasible and may offer curative therapy for those with refractory and relapsed disease.
SUMMARY
HIV-infected persons appear to benefit from most, but not all standard treatments for lymphoma.
综述目的
感染人类免疫缺陷病毒（HIV）会增加患非霍奇金淋巴瘤和霍奇金病的风险。本综述总结过去18个月内的进展。
最新发现
研究人员继续证明，在高效抗逆转录病毒治疗（HAART）时代，许多与用于未感染HIV人群的标准疗法相似的疗法可用于感染HIV的患者。然而，生物学差异确实存在，并非所有治疗方法和结果都可直接转换。一些治疗方法，如利妥昔单抗联合CHOP方案，可能有不可预见的毒性。尽管如此，高剂量治疗似乎是可行的，并且可能为那些难治性和复发性疾病患者提供治愈性治疗。
总结
HIV感染者似乎能从大多数但并非所有淋巴瘤标准治疗中获益。
Zotero 插件